166 related articles for article (PubMed ID: 24348680)
1. Interferon alpha association with neuromyelitis optica.
Asgari N; Voss A; Steenstrup T; Kyvik KO; Stenager E; Lillevang ST
Clin Dev Immunol; 2013; 2013():713519. PubMed ID: 24348680
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.
Feng X; Reder NP; Yanamandala M; Hill A; Franek BS; Niewold TB; Reder AT; Javed A
J Neurol Sci; 2012 Feb; 313(1-2):48-53. PubMed ID: 22036215
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma levels of epithelial neutrophil-activating peptide 78/CXCL5 during the remission of Neuromyelitis optica.
Yang T; Wang S; Zheng Q; Wang L; Li Q; Wei M; Du Z; Fan Y
BMC Neurol; 2016 Jul; 16():96. PubMed ID: 27401736
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against interferon-beta in neuromyelitis optica patients.
Asgari N; Kyvik KO; Steenstrup T; Stenager E; Lillevang ST
J Neurol Sci; 2014 Apr; 339(1-2):52-6. PubMed ID: 24477087
[TBL] [Abstract][Full Text] [Related]
5. Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse.
Wang H; Wang K; Zhong X; Dai Y; Wu A; Li Y; Hu X
J Neuroimmunol; 2012 Feb; 243(1-2):52-5. PubMed ID: 22177277
[TBL] [Abstract][Full Text] [Related]
6. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
[TBL] [Abstract][Full Text] [Related]
7. Low vitamin D-25(OH) level in Indonesian multiple sclerosis and neuromyelitis optic patients.
Kusumadewi W; Imran D; Witjaksono F; Pakasi TA; Rusmana AI; Pangeran D; Marwadhani SS; Maharani K; Estiasari R
Mult Scler Relat Disord; 2018 Oct; 25():329-333. PubMed ID: 30195201
[TBL] [Abstract][Full Text] [Related]
8. Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica.
Masuda H; Mori M; Uzawa A; Muto M; Uchida T; Kuwabara S
Eur J Neurol; 2016 Feb; 23(2):276-81. PubMed ID: 25903772
[TBL] [Abstract][Full Text] [Related]
9. Association of serum gamma-glutamyltransferase and C-reactive proteins with neuromyelitis optica and multiple sclerosis.
Shu Y; Li R; Qiu W; Chang Y; Sun X; Fang L; Chen C; Yang Y; Lu Z; Hu X; Kermode AG
Mult Scler Relat Disord; 2017 Nov; 18():65-70. PubMed ID: 29107207
[TBL] [Abstract][Full Text] [Related]
10. Interferon-beta(1b) treatment in neuromyelitis optica.
Tanaka M; Tanaka K; Komori M
Eur Neurol; 2009; 62(3):167-70. PubMed ID: 19590215
[TBL] [Abstract][Full Text] [Related]
11. Elevated fibrinogen levels in neuromyelitis optica is associated with severity of disease.
Zhang Y; Zhang X; Liu D; Wang H; Pan S; Wang D; Chen X
Neurol Sci; 2016 Nov; 37(11):1823-1829. PubMed ID: 27450097
[TBL] [Abstract][Full Text] [Related]
12. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
Mult Scler; 2012 Oct; 18(10):1480-3. PubMed ID: 22354738
[TBL] [Abstract][Full Text] [Related]
13. Interferon-β1b increases Th2 response in neuromyelitis optica.
Nakajima H; Hosokawa T; Doi Y; Ikemoto T; Ishida S; Kimura F; Hanafusa T
Int J Mol Sci; 2012 Sep; 13(10):12213-23. PubMed ID: 23202893
[TBL] [Abstract][Full Text] [Related]
14. Poor responses to interferon-beta treatment in patients with neuromyelitis optica and multiple sclerosis with long spinal cord lesions.
Wang KC; Lin KH; Lee TC; Lee CL; Chen SY; Chen SJ; Chin LT; Tsai CP
PLoS One; 2014; 9(6):e98192. PubMed ID: 24887452
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica.
Wang KC; Tsai CP; Lee CL; Chen SY; Chin LT; Chen SJ
Neuroscience; 2012 Dec; 226():510-6. PubMed ID: 23122444
[TBL] [Abstract][Full Text] [Related]
16. Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis.
Chang KH; Tseng MY; Ro LS; Lyu RK; Tai YH; Chang HS; Wu YR; Huang CC; Hsu WC; Kuo HC; Chu CC; Chen CM
Clin Chim Acta; 2013 Feb; 417():26-30. PubMed ID: 23262373
[TBL] [Abstract][Full Text] [Related]
17. Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica.
Shimizu Y; Ota K; Ikeguchi R; Kubo S; Kabasawa C; Uchiyama S
J Neuroimmunol; 2013 Oct; 263(1-2):148-51. PubMed ID: 23910387
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
Yamasaki R; Matsushita T; Fukazawa T; Yokoyama K; Fujihara K; Ogino M; Yokota T; Miyamoto K; Niino M; Nomura K; Tomioka R; Tanaka M; Kawachi I; Ohashi T; Kaida K; Matsui M; Nakatsuji Y; Ochi H; Fukaura H; Kanda T; Nagaishi A; Togo K; Mizusawa H; Murai H; Kira J
Mult Scler; 2016 Sep; 22(10):1337-48. PubMed ID: 26564994
[TBL] [Abstract][Full Text] [Related]
19. Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability.
Tomizawa Y; Yokoyama K; Saiki S; Takahashi T; Matsuoka J; Hattori N
J Int Med Res; 2012; 40(4):1483-91. PubMed ID: 22971500
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica.
Wang H; Wang K; Wang C; Zhong X; Qiu W; Hu X
Mult Scler; 2013 Jun; 19(7):926-31. PubMed ID: 23012252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
